Currently, acetylcholinesterase (AChE) inhibition and amyloid-β aggregation are considered as the two pivotal targets for developing anti-Alzheimer’s disease drug(s) [5,6]. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.